Literature DB >> 2178759

Plasma exchange in Canada. The Canadian Apheresis Study Group.

G A Rock1, G W Tricklebank, C A Kasaboski.   

Abstract

Since 1982 the Canadian Apheresis Study Group (CASG) has collected data on plasma exchange activities in Canada. In 1987, 5907 such procedures were carried out on 700 patients for more than 22 different diseases; this represented an increase of 28% over the figure for 1982. A shift in activity has occurred over the years; originally hematologic disorders accounted for most of the procedures; however, in 1987, 60% of the exchanges were done to treat neurologic disorders, mainly myasthenia gravis and acute and chronic Guillain-Barré syndrome. Several prospective randomized clinical trials have recently been completed by the CASG in the hope of determining the optimal application of plasma exchange. These studies, currently under review, include 168 patients with multiple sclerosis, 100 with thrombotic thrombocytopenic purpura and 43 with rapidly progressive glomerulonephritis. Reactions occur in 12% of cases; they are usually minor and are limited to circumoral paresthesia, mild hypertension or hypotension and hives.

Entities:  

Mesh:

Year:  1990        PMID: 2178759      PMCID: PMC1451890     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  15 in total

1.  Mortality in therapeutic haemapheresis.

Authors:  D W Huestis
Journal:  Lancet       Date:  1983-05-07       Impact factor: 79.321

2.  Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.

Authors:  R M Bukowski; J W King; J S Hewlett
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

3.  Complications of plasma exchange.

Authors:  D M Sutton; R C Nair; G Rock
Journal:  Transfusion       Date:  1989-02       Impact factor: 3.157

4.  Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis.

Authors:  D J Wallace; D Goldfinger; R Gatti; C Lowe; P Fan; R Bluestone; J R Klinenberg
Journal:  Arthritis Rheum       Date:  1979-07

5.  Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia.

Authors:  W Stoffel; H Borberg; V Greve
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

6.  Plasmapheresis therapy in myasthenia gravis.

Authors:  P C Dau
Journal:  Muscle Nerve       Date:  1980 Nov-Dec       Impact factor: 3.217

7.  Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome.

Authors:  C M Lockwood; A J Rees; T A Pearson; D J Evans; D K Peters; C B Wilson
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

8.  Thrombotic thrombocytopenic purpura and dose of plasma exchange.

Authors:  E G Taft
Journal:  Blood       Date:  1979-10       Impact factor: 22.113

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

10.  Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial.

Authors:  I L Dwosh; A R Giles; P M Ford; J L Pater; T P Anastassiades
Journal:  N Engl J Med       Date:  1983-05-12       Impact factor: 91.245

View more
  2 in total

1.  Low-density lipoprotein apheresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01

Review 2.  At the Root of 3 "Long" Diseases: Persistent Antigens Inflicting Chronic Damage on the Brain and Other Organs in Gulf War Illness, Long-COVID-19, and Chronic Fatigue Syndrome.

Authors:  Lisa M James; Apostolos P Georgopoulos
Journal:  Neurosci Insights       Date:  2022-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.